KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Minority Interest (2017 - 2020)

Ionis Pharmaceuticals (IONS) has disclosed Minority Interest for 5 consecutive years, with $223.2 million as the latest value for Q3 2020.

  • For Q3 2020, Minority Interest rose 38.08% year-over-year to $223.2 million; the TTM value through Sep 2020 reached $223.2 million, up 38.08%, while the annual FY2019 figure was $213.5 million, 53.47% up from the prior year.
  • Minority Interest hit $223.2 million in Q3 2020 for Ionis Pharmaceuticals, up from $217.6 million in the prior quarter.
  • Across five years, Minority Interest topped out at $223.2 million in Q3 2020 and bottomed at $84.3 million in Q4 2017.
  • Average Minority Interest over 4 years is $157.2 million, with a median of $161.7 million recorded in 2019.
  • Year-over-year, Minority Interest surged 109.74% in 2019 and then rose 15.87% in 2020.
  • Ionis Pharmaceuticals' Minority Interest stood at $84.3 million in 2017, then skyrocketed by 65.05% to $139.1 million in 2018, then soared by 53.47% to $213.5 million in 2019, then rose by 4.58% to $223.2 million in 2020.
  • According to Business Quant data, Minority Interest over the past three periods came in at $223.2 million, $217.6 million, and $210.2 million for Q3 2020, Q2 2020, and Q1 2020 respectively.